SG11201911614XA - Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells - Google Patents

Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells

Info

Publication number: SG11201911614XA
Authority: SG; Singapore
Prior art keywords: tropism; human cells; genetic material; viral particles; recombinant viral
Prior art date: 2017-06-27

Application number

SG11201911614XA

Inventor

Leah Sabin

Christopher Schoenherr

Aris N Economides

Christos Kyratsous

Andrew J Murphy

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-27

Filing date

2018-06-27

Publication date

2020-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201911614X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-06-27 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2020-01-30 Publication of SG11201911614XA publication Critical patent/SG11201911614XA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG11201911614XA 2017-06-27 2018-06-27 Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells SG11201911614XA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762525708P	2017-06-27	2017-06-27
PCT/US2018/039878 WO2019006046A2 (en)	2017-06-27	2018-06-27	Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells

Publications (1)

Publication Number	Publication Date
SG11201911614XA true SG11201911614XA (en)	2020-01-30

Family

ID=63080488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201911614XA SG11201911614XA (en)	2017-06-27	2018-06-27	Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells

Country Status (30)

Country	Link
US (1)	US20200140492A1 (en)
EP (2)	EP3645553B1 (en)
JP (4)	JP2020525020A (en)
KR (2)	KR20200021987A (en)
CN (2)	CN110997699A (en)
AU (2)	AU2018290885B2 (en)
BR (1)	BR112019027866A2 (en)
CA (1)	CA3066950A1 (en)
CL (2)	CL2019003843A1 (en)
CO (1)	CO2019014684A2 (en)
CY (1)	CY1126149T1 (en)
DK (1)	DK3645553T5 (en)
ES (1)	ES2943020T3 (en)
FI (1)	FI3645553T3 (en)
HR (1)	HRP20230538T1 (en)
HU (1)	HUE061908T2 (en)
IL (2)	IL318395A (en)
LT (1)	LT3645553T (en)
MA (1)	MA49514B1 (en)
MD (1)	MD3645553T2 (en)
MX (2)	MX2020000246A (en)
PE (2)	PE20251541A1 (en)
PH (1)	PH12019550269B1 (en)
PL (1)	PL3645553T3 (en)
PT (1)	PT3645553T (en)
RS (1)	RS64233B1 (en)
SG (1)	SG11201911614XA (en)
SI (1)	SI3645553T1 (en)
SM (1)	SMT202300168T1 (en)
WO (1)	WO2019006046A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3151866B1 (en)	2014-06-09	2023-03-08	Voyager Therapeutics, Inc.	Chimeric capsids
AU2019227910B2 (en) *	2018-02-28	2025-07-17	The Regents Of The University Of California	A modular system for gene and protein delivery based on AAV
EP3774926A1 (en)	2018-04-05	2021-02-17	Bio-Rad ABD Serotec GmbH	Display systems for proteins of interest
GB201903479D0 (en)	2019-03-14	2019-05-01	Univ Oxford Innovation Ltd	Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof
AU2020243460A1 (en)	2019-03-18	2021-10-07	Bio-Rad Abd Serotec Gmbh	Protection of SpyTag-containing periplasmic fusion proteins from protease Tsp and ompT degradation
KR20220011664A (en) *	2019-05-24	2022-01-28	리제너론 파마슈티칼스 인코포레이티드	Modified viral particles and uses thereof
WO2020251937A1 (en) *	2019-06-11	2020-12-17	Chevron U.S.A. Inc.	Membranes for contaminant removal from natural gas and methods for use thereof
AU2020308463A1 (en) *	2019-06-26	2022-02-17	Ap Biosciences, Inc.	Antibodies for T-cell activation
GB201915905D0 (en) *	2019-11-01	2019-12-18	Spybiotech Ltd	Viruses with modified capsid proteins
EP4055034A4 (en) *	2019-11-08	2024-05-29	President And Fellows Of Harvard College	VIRAL CAPSID POLYPEPTIDES
CN114634578B (en) *	2020-12-15	2024-04-02	榕森生物科技(北京)有限公司	Vaccine compositions against novel coronavirus infections
CN114632148B (en) *	2020-12-15	2024-08-09	榕森生物科技(北京)有限公司	Pathogen-like antigen vaccine and method for producing the same
EP4426359A1 (en)	2021-11-04	2024-09-11	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to skeletal muscle
CN114213505B (en) *	2021-12-10	2022-09-20	和元生物技术（上海）股份有限公司	Adeno-associated virus mutant suitable for specifically infecting U87-MG cells
CA3256953A1 (en)	2022-05-09	2023-11-16	Regeneron Pharmaceuticals, Inc.	Vectors and methods for in vivo antibody production
EP4536836A1 (en)	2022-06-07	2025-04-16	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
JP2025525792A (en)	2022-07-29	2025-08-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Viral particles retargeted to transferrin receptor 1
JP2025538220A (en)	2022-11-14	2025-11-26	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240168018A1 (en)	2022-11-18	2024-05-23	Regeneron Pharmaceuticals, Inc.	Methods for detecting and evaluating viruses and virus-like particles
WO2024124019A2 (en) *	2022-12-07	2024-06-13	Ginkgo Bioworks, Inc.	Aav vectors targeting hematopoietic stem cells
CN120677178A (en)	2023-02-13	2025-09-19	瑞泽恩制药公司	Treatment of muscle-related disorders with anti-human CACNG1 antibodies
CN121039163A (en)	2023-05-02	2025-11-28	瑞泽恩制药公司	Anti-human M-cadherin (CDH 15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
TW202515999A (en)	2023-06-20	2025-04-16	美商再生元醫藥公司	Methods for purifying filled adeno-associated virus capsids
WO2025018388A1 (en) *	2023-07-20	2025-01-23	学校法人自治医科大学	Antibacterial capsid, therapeutic composition, bactericide, method for removing bacteria, method for killing bacteria, method for treating animals, method for introducing gene, method for adding bacterial function, method for producing antibacterial capsid, method for labeling antibacterial capsid, and method for intracellular delivery of antibacterial capsid
CN119552829A (en) *	2023-09-01	2025-03-04	北京昌平实验室	Adeno-associated virus engineered with targeted gene editing enzyme and its pharmaceutical composition
WO2025054526A1 (en)	2023-09-07	2025-03-13	Regeneron Pharmaceuticals, Inc.	Production and purification of covalently surface modified adeno-associated virus
WO2025097030A1 (en) *	2023-11-02	2025-05-08	Oregon State University	Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
WO2025111473A1 (en)	2023-11-21	2025-05-30	Regeneron Pharmaceuticals, Inc.	Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2025151796A1 (en)	2024-01-11	2025-07-17	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to nervous system tissues
WO2025155923A1 (en)	2024-01-17	2025-07-24	The Broad Institute, Inc.	Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025160340A2 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
CN117723749B (en) *	2024-02-07	2024-06-04	南昌大学	Dynamic light scattering immunosensory detection method based on molecular adhesive
US20250277048A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025217163A2 (en)	2024-04-08	2025-10-16	The Broad Institute, Inc.	Novel aav capsids binding to human cd59
WO2025217174A1 (en)	2024-04-08	2025-10-16	The Broad Institute, Inc.	Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
CN119529113A (en) *	2024-11-28	2025-02-28	浙江大学	A nano antigen display platform based on PCV2 VLPs and its preparation method and application
CN120519522B (en) *	2025-07-23	2025-11-18	南昌大学第一附属医院	Universal engineering exosome construction method based on bidirectional load module

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1286981C (en) *	2004-11-30	2006-11-29	华中科技大学同济医学院附属同济医院	Recombinant adeno-associated virus expressing human CYP2J2 antisense gene and preparation method thereof
ES2602610T3 (en)	2007-05-31	2017-02-21	Medigene Ag	Mutated structural protein of a parvovirus
MY172472A (en)	2009-12-10	2019-11-26	Regeneron Pharma	Mice that make heavy chain antibodies
GB201002362D0 (en)	2010-02-11	2010-03-31	Isis Innovation	Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
AR094403A1 (en) *	2013-01-11	2015-07-29	Hoffmann La Roche	ANTI-HER3 ANTIBODY COMBINATION THERAPY
BR112016021572A2 (en)	2014-03-21	2017-10-03	Regeneron Pharma	METHODS FOR PREPARING A GENETICALLY MODIFIED NON-HUMAN ANIMAL AND FOR PRODUCING BINDING PROTEINS, HYBRIDOMA, NUCLEIC ACID, CELL, AND, BINDING PROTEIN
US20160018835A1 (en)	2014-07-18	2016-01-21	Retroficiency, Inc.	System and method for virtual energy assessment of facilities
DE16703049T1 (en) *	2015-01-15	2018-07-12	University Of Copenhagen	VIRUSUAL PARTICLES WITH EFFICIENT EPITOPHONE
CA2977434A1 (en)	2015-02-26	2016-09-01	Var2 Pharmaceuticals Aps	Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
EP3141600A1 (en)	2015-09-11	2017-03-15	Institut National de la Recherche Agronomique	Nepovirus coat protein fusion polypeptides and their use
WO2018035503A1 (en)	2016-08-18	2018-02-22	The Regents Of The University Of California	Crispr-cas genome engineering via a modular aav delivery system
AU2019227910B2 (en) *	2018-02-28	2025-07-17	The Regents Of The University Of California	A modular system for gene and protein delivery based on AAV

2018
- 2018-06-27 LT LTEPPCT/US2018/039878T patent/LT3645553T/en unknown
- 2018-06-27 HR HRP20230538TT patent/HRP20230538T1/en unknown
- 2018-06-27 KR KR1020207001284A patent/KR20200021987A/en not_active Ceased
- 2018-06-27 MX MX2020000246A patent/MX2020000246A/en unknown
- 2018-06-27 WO PCT/US2018/039878 patent/WO2019006046A2/en not_active Ceased
- 2018-06-27 MD MDE20200493T patent/MD3645553T2/en unknown
- 2018-06-27 HU HUE18749636A patent/HUE061908T2/en unknown
- 2018-06-27 CN CN201880054254.8A patent/CN110997699A/en active Pending
- 2018-06-27 DK DK18749636.9T patent/DK3645553T5/en active
- 2018-06-27 JP JP2019572025A patent/JP2020525020A/en active Pending
- 2018-06-27 SG SG11201911614XA patent/SG11201911614XA/en unknown
- 2018-06-27 CN CN202310837502.9A patent/CN116891534A/en active Pending
- 2018-06-27 ES ES18749636T patent/ES2943020T3/en active Active
- 2018-06-27 PE PE2024003143A patent/PE20251541A1/en unknown
- 2018-06-27 RS RS20230411A patent/RS64233B1/en unknown
- 2018-06-27 FI FIEP18749636.9T patent/FI3645553T3/en active
- 2018-06-27 SM SM20230168T patent/SMT202300168T1/en unknown
- 2018-06-27 MA MA49514A patent/MA49514B1/en unknown
- 2018-06-27 PT PT187496369T patent/PT3645553T/en unknown
- 2018-06-27 PE PE2019002651A patent/PE20200895A1/en unknown
- 2018-06-27 KR KR1020257019410A patent/KR20250091321A/en active Pending
- 2018-06-27 EP EP18749636.9A patent/EP3645553B1/en active Active
- 2018-06-27 BR BR112019027866-4A patent/BR112019027866A2/en unknown
- 2018-06-27 EP EP23153644.2A patent/EP4219529A1/en active Pending
- 2018-06-27 AU AU2018290885A patent/AU2018290885B2/en active Active
- 2018-06-27 SI SI201830908T patent/SI3645553T1/en unknown
- 2018-06-27 IL IL318395A patent/IL318395A/en unknown
- 2018-06-27 PH PH1/2019/550269A patent/PH12019550269B1/en unknown
- 2018-06-27 CA CA3066950A patent/CA3066950A1/en active Pending
- 2018-06-27 PL PL18749636.9T patent/PL3645553T3/en unknown
- 2018-06-27 US US16/625,207 patent/US20200140492A1/en active Pending
2019
- 2019-12-19 IL IL271570A patent/IL271570A/en unknown
- 2019-12-24 CO CONC2019/0014684A patent/CO2019014684A2/en unknown
- 2019-12-26 CL CL2019003843A patent/CL2019003843A1/en unknown
2020
- 2020-01-08 MX MX2023009051A patent/MX2023009051A/en unknown
- 2020-12-30 CL CL2020003438A patent/CL2020003438A1/en unknown
2022
- 2022-10-27 JP JP2022172414A patent/JP2022186991A/en active Pending
2023
- 2023-06-14 CY CY20231100276T patent/CY1126149T1/en unknown
- 2023-07-12 AU AU2023204611A patent/AU2023204611B2/en active Active
2024
- 2024-04-03 JP JP2024060495A patent/JP2024071769A/en active Pending
2025
- 2025-06-26 JP JP2025108609A patent/JP2025129257A/en active Pending

Also Published As

Publication number	Publication date
AU2018290885A1 (en)	2020-01-16
MX2023009051A (en)	2023-08-10
IL318395A (en)	2025-03-01
CL2019003843A1 (en)	2020-07-24
WO2019006046A2 (en)	2019-01-03
LT3645553T (en)	2023-04-25
PL3645553T3 (en)	2023-07-17
MA49514A (en)	2020-05-06
RU2020101596A (en)	2021-07-27
SMT202300168T1 (en)	2023-07-20
BR112019027866A2 (en)	2020-07-07
HUE061908T2 (en)	2023-09-28
PE20251541A1 (en)	2025-06-05
FI3645553T3 (en)	2023-05-22
CN110997699A (en)	2020-04-10
MA49514B1 (en)	2023-06-28
DK3645553T5 (en)	2024-08-26
CY1126149T1 (en)	2023-11-15
PH12019550269A1 (en)	2021-01-11
CL2020003438A1 (en)	2021-07-23
MD3645553T2 (en)	2023-07-31
IL271570A (en)	2020-02-27
HRP20230538T1 (en)	2023-08-04
JP2025129257A (en)	2025-09-04
JP2020525020A (en)	2020-08-27
CN116891534A (en)	2023-10-17
PT3645553T (en)	2023-05-08
CO2019014684A2 (en)	2020-01-17
PH12019550269B1 (en)	2024-05-22
ES2943020T3 (en)	2023-06-08
AU2023204611B2 (en)	2025-10-30
EP4219529A1 (en)	2023-08-02
US20200140492A1 (en)	2020-05-07
MX2020000246A (en)	2020-08-10
RS64233B1 (en)	2023-06-30
WO2019006046A3 (en)	2019-02-14
RU2020101596A3 (en)	2022-03-22
DK3645553T3 (en)	2023-05-22
JP2022186991A (en)	2022-12-15
CA3066950A1 (en)	2019-01-03
EP3645553A2 (en)	2020-05-06
JP2024071769A (en)	2024-05-24
KR20250091321A (en)	2025-06-20
AU2018290885B2 (en)	2023-07-27
PE20200895A1 (en)	2020-09-08
SI3645553T1 (en)	2023-06-30
KR20200021987A (en)	2020-03-02
AU2023204611A1 (en)	2023-08-03
EP3645553B1 (en)	2023-03-15

Publication	Publication Date	Title
IL271570A (en)	2020-02-27	Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
IL271573A (en)	2020-02-27	Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
IL266045A (en)	2019-06-30	Secretable variant immunomodulatory proteins and engineered cell therapy
IL288233A (en)	2022-01-01	Modified viral particles and uses thereof
HUE064032T2 (en)	2024-02-28	Positive electrode material and application thereof
ZA201702632B (en)	2019-06-26	Compositions comprising recombinant bacillus cells and an insecticide
SG11202103024RA (en)	2021-04-29	Culture material and use thereof
SG11201706445SA (en)	2017-09-28	Enhanced delivery of viral particles to the striatum and cortex
PL3471177T3 (en)	2021-10-04	Negative electrode active material and negative electrode including the same
IL275550A (en)	2020-08-31	Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
IL290297A (en)	2022-04-01	Modified cytotoxic t cells and methods of use thereof
SG11202110541QA (en)	2021-10-28	Multi-respiratory virus antigen-specific t cells and methods of making and using the same therapeutically
ZA202000595B (en)	2021-04-28	Novel therapeutic enzyme fusion protein and use thereof
PL3422445T3 (en)	2021-07-19	Negative electrode material comprising silicon flakes and preparing method of silicon flakes
GB201901166D0 (en)	2019-03-20	Genetic construct and uses thereof
GB2573931B (en)	2022-01-26	Electrode material and application thereof
ZA201904386B (en)	2023-01-25	S-arrestin peptides and therapeutic uses thereof
PT3526244T (en)	2023-12-11	Peptides derived from the propeptide ntsr3 and their use in the treatment of depression
HK40072139A (en)	2022-11-18	Modified viral particles and uses thereof
HK40005456A (en)	2020-05-08	Secretable variant immunomodulatory proteins and engineered cell therapy
HK1259053A1 (en)	2019-11-22	Modified silicon particle electrodes and methods
HK40007738A (en)	2020-06-05	Particles for delivery of proteins and peptides
GB201417148D0 (en)	2014-11-12	Eukaryotic expression vector encoding canine interleukin 12 for cancer gene therapy and the use thereof